Overview

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this program is to provide Daclatasvir in combination with Sofosbuvir with or without Ribavirin to subjects with chronic Hepatitis C who are at a high risk of liver decompensation or death within 12 months if left untreated and who have no available therapeutic options.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Ribavirin
Sofosbuvir